Marc Botteman
Overview
Explore the profile of Marc Botteman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simoes E, Botteman M, Chirikov V
J Infect Dis
. 2023 Aug;
229(4):1112-1122.
PMID: 37625899
Background: The objective was to report critical respiratory syncytial virus (RSV)-related epidemiological and healthcare resource utilization measures among Japanese children stratified by gestational and chronological age groups. Methods: The JMDC...
2.
Chirikov V, Botteman M, Simoes E
Clinicoecon Outcomes Res
. 2022 Nov;
14:699-714.
PMID: 36389101
Background: The objective of this study was to estimate the long-term healthcare utilization and cost burden of RSV by chronological age of diagnosis (Year 1, Year 2 and Years 3-5...
3.
George D, Mohamed A, Tsai J, Karimi M, Ning N, Jayade S, et al.
Cancer Med
. 2022 Oct;
12(5):6040-6055.
PMID: 36226867
Background: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration-resistant prostate cancer (mCRPC) can facilitate shared-decision making for optimal management. This study sought to...
4.
Zeidan A, Tsai J, Karimi M, Schmier J, Jayade S, Zormpas E, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Jun;
22(9):e853-e866.
PMID: 35729009
Introduction/background: Therapy with infused or injected hypomethylating agents (HMAs) may lead to higher treatment administration burden (ie, local reaction, visit frequency and duration) vs. oral HMAs. OBJECTIVES: To reveal preferences...
5.
Zeidan A, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Oct;
22(3):e185-e198.
PMID: 34674983
Background: Until recently, patients with MDSs could receive HMAs via intravenous (IV) or subcutaneous (SC) administration. An oral HMA was recently approved as an alternative to IV/SC administration. This study...
6.
Kale H, Qureshi Z, Shah R, Khandker R, Botteman M, Meng W, et al.
Adv Ther
. 2021 Aug;
38(10):5221-5237.
PMID: 34463922
Introduction: Insomnia diagnosis has been associated with a significant clinical and economic burden on patients and healthcare systems. This study examined changes in healthcare resource use (HCRU) and costs in...
7.
Reni M, Braverman J, Hendifar A, Li C, Macarulla T, Oh D, et al.
Ann Surg Oncol
. 2021 Apr;
28(12):7545-7554.
PMID: 33813673
Background: Although the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-PAN26 is widely used to assess health-related quality of life (HRQoL), its group-level minimal important difference (MID) and...
8.
Su J, Li N, Joshi N, Ng X, Botteman M, Shah R, et al.
Haemophilia
. 2020 Sep;
26(6):e291-e299.
PMID: 32937681
Introduction: Long-acting products are changing the haemophilia A treatment landscape by giving patients and caregivers treatment options with varying product attributes. Aim: A discrete choice experiment (DCE) was used to...
9.
Aly A, Johnson C, Doleh Y, Chirikov V, Botteman M, Shenolikar R, et al.
J Clin Pathw
. 2020 Aug;
6(4):51-60.
PMID: 32832698
Background: Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer's perspective, the lifetime costs among patients diagnosed with UC according...
10.
Srinivas S, Mohamed A, Appukkuttan S, Botteman M, Ng X, Joshi N, et al.
Cancer Med
. 2020 Jul;
9(18):6586-6596.
PMID: 32725755
Background: Recently approved second-generation androgen receptor inhibitors (SGARIs) for non-metastatic castration-resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to...